Emergent Biosolutions (EBS) Competitors $8.85 +0.03 (+0.34%) Closing price 08/15/2025 03:59 PM EasternExtended Trading$8.90 +0.05 (+0.56%) As of 08/15/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EBS vs. JNJ, BCRX, CLDX, NVAX, DVAX, INVA, MNKD, OPK, GERN, and ZBIOShould you be buying Emergent Biosolutions stock or one of its competitors? The main competitors of Emergent Biosolutions include Johnson & Johnson (JNJ), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), and Zenas BioPharma (ZBIO). These companies are all part of the "medical" sector. Emergent Biosolutions vs. Its Competitors Johnson & Johnson BioCryst Pharmaceuticals Celldex Therapeutics Novavax Dynavax Technologies Innoviva MannKind OPKO Health Geron Zenas BioPharma Emergent Biosolutions (NYSE:EBS) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Which has more risk and volatility, EBS or JNJ? Emergent Biosolutions has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Is EBS or JNJ more profitable? Johnson & Johnson has a net margin of 25.00% compared to Emergent Biosolutions' net margin of 16.38%. Johnson & Johnson's return on equity of 32.49% beat Emergent Biosolutions' return on equity.Company Net Margins Return on Equity Return on Assets Emergent Biosolutions16.38% 24.63% 8.97% Johnson & Johnson 25.00%32.49%13.00% Does the media favor EBS or JNJ? In the previous week, Johnson & Johnson had 63 more articles in the media than Emergent Biosolutions. MarketBeat recorded 77 mentions for Johnson & Johnson and 14 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.55 beat Emergent Biosolutions' score of 0.86 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Johnson & Johnson 71 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable earnings and valuation, EBS or JNJ? Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEmergent Biosolutions$1.04B0.45-$190.60M$2.453.61Johnson & Johnson$88.82B4.79$14.07B$9.3518.90 Do analysts prefer EBS or JNJ? Emergent Biosolutions currently has a consensus price target of $14.33, suggesting a potential upside of 61.96%. Johnson & Johnson has a consensus price target of $174.50, suggesting a potential downside of 1.28%. Given Emergent Biosolutions' stronger consensus rating and higher probable upside, research analysts plainly believe Emergent Biosolutions is more favorable than Johnson & Johnson.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Emergent Biosolutions 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Johnson & Johnson 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.65 Do institutionals and insiders hold more shares of EBS or JNJ? 78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 1.2% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryJohnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks. Get Emergent Biosolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EBS vs. The Competition Export to ExcelMetricEmergent BiosolutionsMED IndustryMedical SectorNYSE ExchangeMarket Cap$470.56M$3.10B$5.68B$20.90BDividend YieldN/A2.23%3.79%3.58%P/E Ratio3.6120.8931.0828.00Price / Sales0.45364.47466.2155.78Price / Cash4.5942.3037.4023.77Price / Book0.888.659.095.26Net Income-$190.60M-$54.65M$3.26B$994.11M7 Day Performance3.51%6.56%7.36%1.80%1 Month Performance26.66%7.53%5.47%1.74%1 Year Performance-17.60%13.69%30.61%13.36% Emergent Biosolutions Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EBSEmergent Biosolutions4.7141 of 5 stars$8.85+0.3%$14.33+62.0%+2.2%$470.56M$1.04B3.612,420News CoverageJNJJohnson & Johnson4.8419 of 5 stars$173.98+0.4%$174.50+0.3%+11.1%$418.99B$90.63B18.61138,100Positive NewsBCRXBioCryst Pharmaceuticals4.249 of 5 stars$8.20-1.2%$16.70+103.7%+9.7%$1.72B$450.71M-45.55530Insider TradeCLDXCelldex Therapeutics1.6058 of 5 stars$20.01-3.1%$50.11+150.4%-23.0%$1.33B$7.02M-6.65150NVAXNovavax4.634 of 5 stars$8.04-4.0%$15.86+97.4%-24.2%$1.31B$1.08B3.521,990DVAXDynavax Technologies4.4823 of 5 stars$10.48+1.5%$24.33+132.2%-4.9%$1.26B$294.62M-22.78350INVAInnoviva4.3854 of 5 stars$19.64+7.1%$42.75+117.6%+13.6%$1.23B$358.71M63.36100News CoveragePositive NewsAnalyst UpgradeAnalyst RevisionHigh Trading VolumeMNKDMannKind3.0809 of 5 stars$3.42-2.9%$9.71+184.3%-28.1%$1.05B$285.50M31.07400OPKOPKO Health4.4092 of 5 stars$1.30+4.0%$2.75+111.5%-13.3%$1.03B$713.10M-5.202,997GERNGeron3.3521 of 5 stars$1.36+6.3%$4.19+207.9%-67.5%$867.70M$164.45M-10.46229Analyst RevisionZBIOZenas BioPharma1.7156 of 5 stars$14.90+1.8%$36.67+146.1%N/A$623.27M$5M-4.20N/ANews CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies JNJ Alternatives BCRX Alternatives CLDX Alternatives NVAX Alternatives DVAX Alternatives INVA Alternatives MNKD Alternatives OPK Alternatives GERN Alternatives ZBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:EBS) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredThe Debt Crisis Is Coming—Will You Be Ready?A full-blown "economic heart attack" is coming—and the markets aren't ready. The problem? Exploding U.S. de...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent Biosolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent Biosolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access